肿瘤细胞治疗的进展与前景:从 T 细胞到干细胞的探索
Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.
全球癌症负担日益加重,亟需创新的治疗策略。
ALL SOURCES
Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.
全球癌症负担日益加重,亟需创新的治疗策略。
Cell-Type-Tailored Hydrogels for Adoptive Cell Therapy in Cancer.
水凝胶赋能的过继细胞疗法(ACT)为改善实体瘤的细胞免疫治疗提供了一种局部且可控的策略。
Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives.
CAR-T 细胞疗法在血液系统恶性肿瘤中已取得显著成功,但在实体瘤中面临重大障碍。
Quantitative Characterization of Innate and Adaptive Pharmacology of Allogeneic anti-CD20 Chimeric Antigen Receptor (CAR) Vδ1 γδ T cells using Multisc
Gamma Delta (γδ) T 细胞目前正被评估作为传统 alpha-beta (αβ) T 细胞的治疗替代方案,因其具有更优的安全性特征和增强的组织滞留特性。
Arming Vδ2 T Cells with Chimeric Antigen Receptors to Combat Cancer.
免疫治疗已成为肿瘤治疗领域一种有前景的方法,其中嵌合抗原受体(CAR)T 细胞治疗展现出显著的成功。
mRNA-Engineered CD5-CAR-γδT(CD5-) Cells for the Immunotherapy of T-Cell Acute Lymphoblastic Leukemia.
CAR-T 细胞疗法的临床试验已在治疗实体瘤和血液系统恶性肿瘤方面展现出显著成功。
Re-Tooling of γδ T Cells for Cancer Immunotherapy Using Advanced Manufacturing and Genetic Engineering.
使用体外扩增的自体T细胞进行的过继性免疫治疗在多种癌症类型的治疗中取得了显著成功。
Better by design: What to expect from novel CAR-engineered cell therapies?
嵌合抗原受体(CAR)技术,尤其是CAR-T细胞,自证明对多种血液系统恶性肿瘤有效以来,已成为癌症免疫治疗中一种新的强大工具。
Potential of gamma/delta T cells for solid tumor immunotherapy.
需要更全面的研究来建立标准化治疗方案,旨在提高接受T细胞免疫治疗的肿瘤患者的生活质量和生存率。
CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors.
嵌合抗原受体(CAR)工程化细胞疗法代表了癌症免疫治疗的一项里程碑式进展。
共 10 条
MEMBER ACCOUNT
登录成功会直接打开下一页。